Sign In
Buy HBIO
$6.50
+0.0400 (+0.619%)
At Close: Jun 03, 2026
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
09:30am, Tuesday, 12'th May 2026
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
Harvard Bioscience Announces First Quarter 2026 Financial Results
07:30am, Tuesday, 12'th May 2026
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 20
Harvard Bioscience to Participate in Upcoming Investor Conferences
07:30am, Thursday, 07'th May 2026
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
07:30am, Tuesday, 28'th Apr 2026
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12
Harvard Bioscience Q4 Earnings Call Highlights
01:14am, Saturday, 14'th Mar 2026
Harvard Bioscience (NASDAQ: HBIO) executives highlighted a year of "foundation building" and cost and balance sheet actions while outlining expectations for a return to growth in 2026 during the compa
Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
10:02am, Thursday, 12'th Mar 2026
Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
07:30am, Thursday, 12'th Mar 2026
Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full Yea
Harvard Bioscience Announces Reverse Stock Split
04:01pm, Friday, 06'th Mar 2026
Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: H
Harvard Bioscience (NASDAQ:HBIO) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened
04:14am, Wednesday, 04'th Mar 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $0.
Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum
07:30am, Tuesday, 03'rd Mar 2026
HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financ
Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
07:30am, Thursday, 26'th Feb 2026
HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on Marc
Harvard Bioscience (NASDAQ:HBIO) Stock Crosses Below 200 Day Moving Average – Time to Sell?
04:56am, Tuesday, 24'th Feb 2026
Shares of Harvard Bioscience, Inc. (NASDAQ: HBIO - Get Free Report) crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.56 and traded as low
Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and
Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth
04:30pm, Thursday, 29'th Jan 2026
Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027
Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package
07:30am, Wednesday, 17'th Dec 2025
Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board o
